The standard of care for T1D includes frequent blood glucose monitoring along with exogenous insulin administration, a non-physiologic treatment often associated with a greater burden of disease and reduced quality of life for patients (7–10). This evidence concerns the gene INS and type 1 diabetes mellitus.